Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Salagen
(United States) [Available]Synonyms :
Pilocarpine
Class :
cholinergic agonists and Salivary Stimulants
Brand Name :
Salagen
(United States) [Available]Synonyms :
Pilocarpine
Class :
cholinergic agonists and Salivary Stimulants
Dosage Forms & Strengths
Tablet
5 mg
7.5 mg
1
drop
1%, 2%, or 4% solution 4 times a day
Open Angle Or Secondary Glaucoma
1 drop of 1%, 2%, or 4% solution 4 times a day
1 drop of 1%, 2%, or 4% solution 4 times a day
One drop of 1%, 2%, or 4% solution
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
it may increase the risk of adverse effects of cholinergic agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may decrease the toxic effect of beta blockers
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may decrease the cholinergic effect of cholinergic agents
may increase the toxic effect of anti-cholinergic agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the toxic effect of Acetylcholinesterase Inhibitors
may have an increasingly adverse effects when combined with pilocarpine
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
may have an increasingly adverse effect when combined with cholinergic agonists
Pilocarpine activates muscarinic receptors (fromM1 to M5), with primary effects through M3 receptors in exocrine glands and smooth muscles.
>10%
Dizziness
Chills
Nausea
Headache
Flushing
Urinary frequency
Rhinitis
Sweating
Diaphoresis
1-10%
Vomiting
Hypertension
Asthenia
Pain
Dyspepsia
Lacrimation
Amblyopia
Frequency Not Defined
Bradycardia
Hypotension
Tachycardia
Confusion
None
Contraindications/caution:
Contraindications:
Hypersensitivity
Uncontrolled Asthma
Cautions:
Mild to Moderate Hepatic Impairment
Cardiovascular Diseases
Cholelithiasis
Respiratory Disorders
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology: Pilocarpine activates M3 receptors in exocrine glands and smooth muscles to increased secretion. They activate muscarinic receptors in the gastrointestinal tract to enhance peristalsis.
Pharmacodynamics: Pilocarpine contracts pupil muscle and reduces eye pressure to enhance aqueous humor outflow through meshwork.
Pharmacokinetic:
Absorption:
It reaches peak plasma time in 0.85 to 1.25 hours.
Excretion and elimination:
It has half-life of 0.76 to 1.35 hours.
It is taken orally in the form of tablet.
Generic Name: Pilocarpine
Pronunciation: pie-loh-KAR-peen
Why do we use Pilocarpine?
Pilocarpine is used to treat Sjogren’s syndrome. It is also used in radiation-induced xerostomia to treat dry mouth. It is used in treatment of intraocular pressure in open-angle glaucoma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
